Format

Send to:

Choose Destination
See comment in PubMed Commons below
Curr Opin Pulm Med. 2009 Jul;15(4):366-70. doi: 10.1097/MCP.0b013e32832b98eb.

Serum and pleural fluid biomarkers for mesothelioma.

Author information

  • 1National Centre for Asbestos Related Diseases, Western Australian Institute of Medical Research, University of Western Australia, 4th Floor, G block, Sir Charles Gairdner Hospital, Verdun St, Nedlands, WA 6009, Australia. creaneyj@cyllene.uwa.edu.au

Abstract

PURPOSE OF REVIEW:

Malignant mesothelioma is an asbestos-induced, aggressive tumour. In centres across the world, research has focused on evaluating biomarkers for malignant mesothelioma screening, diagnosis, prognostication and monitoring. With the incidence of malignant mesothelioma expected to increase, it is timely to review the current status of biomarkers in this field.

RECENT FINDINGS:

The majority of recent studies have evaluated the commercial MESOMARK assay in a diagnostic setting. Studies have clarified that soluble-shed mesothelin as well as mesothelin-related peptide are targets of the assay. The assay sensitivity ranges from 50% at diagnosis to 84% in advanced disease. The assay has a high level of specificity relative to benign lung and pleural conditions and is positive in 10-15% of other malignancies. In a prospective screen of 538 asbestos-exposed workers, 2.8% were positive; one had lung cancer that was subsequently successfully treated. The biomarkers megakaryocyte potentiating factor, osteopontin and CA125, either alone or in combination with soluble mesothelin, have also been assessed.

SUMMARY:

To date, soluble mesothelin remains the best available biomarker for malignant mesothelioma. However, a lack of sensitivity for early-stage disease and for all malignant mesothelioma histologies provides motivation for the search of novel malignant mesothelioma biomarkers with greater sensitivity, especially for very early disease.

PMID:
19417672
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Lippincott Williams & Wilkins
    Loading ...
    Write to the Help Desk